Metformin use associated with decreased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Cancer, researchers from the University of Chicago in Chicago, Illinois, have found that metformin use is associated with a decreased risk of developing colorectal cancer.
Metformin is typically the first-line oral treatment for patients with type 2 diabetes mellitus. For the study, researchers sought to examine the effects of metformin on colorectal cancer incidence in a U.S. population.
Using MarketScan databases, researchers identified patients with diabetes and colorectal cancer with each case being matched with up to two controls. The mean age of participants was 57 years for cases and 55 years for controls.
Results showed that metformin use was associated with a 15% risk reduction for the development of colorectal cancer, which was reduced to 12% after adjusting for health care use.
Researchers also found that there was no significant association between metformin dose, duration of treatment, or total exposure and risk of colorectal cancer.
Metformin use is associated with a decreased risk of developing colorectal cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|